ArticleFuture science OA2025
Amniotic fluid MSCs for scaffold-free cartilage repair: spheroid fusion and chondrogenic microtissue development.
Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in 3D-Printed Drug Delivery and Screening Platforms for Bone Disease Therapy.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundArticular cartilage injuries are challenging due to limited regenerative capacity, causing chronic pain and impaired mobility. Current treatments are often inadequate, necessitating novel cartilage repair approaches. This study investigates amniotic fluid-derived mesenchymal stromal cells (AF-MSC) as a promising cell source for tissue engineering. RESEARCH DESIGN AND
methodCartilage-like microtissues were produced by differentiating AF-MSC into chondrocytes within a 3D culture system. Using a 3D-printed non-adhesive micromold, AF-MSC spheroids were formed and fused into larger microtissues. Spheroids were characterized for morphology, viability, and extracellular matrix (ECM) production. The mechanical properties of resulting microtissues were compared to native cartilage and agarose hydrogel.
resultsAF-MSC proved a viable, scalable cell source for cartilage microtissues. Spheroid fusion created structures with mechanical properties and ECM components resembling native cartilage.
conclusionsAF-MSCs differentiated into chondrocytes when stimulated with TGF-β3 in a 3D micromolded culture, forming uniform, viable spheroids with robust ECM production and mechanical properties. These spheroids fused into neocartilage microtissue, showing potential for regenerative medicine, especially osteoarthritis treatment and drug testing. Further research should optimize conditions and evaluate long-term biomechanical performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.